Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Valeant Pharmaceuticals International, Inc. - Product Pipeline Review - 2016', provides an overview of the Valeant Pharmaceuticals International, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Valeant Pharmaceuticals International, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Valeant Pharmaceuticals International, Inc. - The report provides overview of Valeant Pharmaceuticals International, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Valeant Pharmaceuticals International, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Valeant Pharmaceuticals International, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons to buy - Evaluate Valeant Pharmaceuticals International, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Valeant Pharmaceuticals International, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Valeant Pharmaceuticals International, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Valeant Pharmaceuticals International, Inc. Snapshot 7 Valeant Pharmaceuticals International, Inc. Overview 7 Key Information 7 Key Facts 7 Valeant Pharmaceuticals International, Inc. - Research and Development Overview 8 Key Therapeutic Areas 8 Valeant Pharmaceuticals International, Inc. - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Combination Treatment Modalities 13 Pipeline Products - Partnered Products 14 Partnered Products/Combination Treatment Modalities 15 Pipeline Products - Out-Licensed Products 16 Out-Licensed Products/Combination Treatment Modalities 17 Valeant Pharmaceuticals International, Inc. - Pipeline Products Glance 18 Valeant Pharmaceuticals International, Inc. - Late Stage Pipeline Products 18 Pre-Registration Products/Combination Treatment Modalities 18 Phase III Products/Combination Treatment Modalities 19 Valeant Pharmaceuticals International, Inc. - Clinical Stage Pipeline Products 20 Phase II Products/Combination Treatment Modalities 20 Phase I Products/Combination Treatment Modalities 21 Valeant Pharmaceuticals International, Inc. - Early Stage Pipeline Products 22 Preclinical Products/Combination Treatment Modalities 22 Valeant Pharmaceuticals International, Inc. - Unknown Stage Pipeline Products 23 Unknown Products/Combination Treatment Modalities 23 Valeant Pharmaceuticals International, Inc. - Drug Profiles 24 brodalumab 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 (halobetasol propionate + tazarotene) 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 budesonide 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 IDP-122 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 loteprednol etabonate next generation 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 rifaximin DR 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BLO-020 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 ezogabine 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 IDP-120 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 IDP-121 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 IDP-125 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 IDP-126 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 IDP-127 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 IDP-128 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 IDP-129 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 IDP-130 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 IDP-131 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 lapuleucel-T 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 ribavirin 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 SAL-021 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Product Description 51 Mechanism of Action 51 R&D Progress 51 SPT-201 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 metyrosine 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 BLO-021 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 IDP-123 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 IDP-124 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 VALBRO-03 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Valeant Pharmaceuticals International, Inc. - Pipeline Analysis 58 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Target 58 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Route of Administration 60 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Molecule Type 61 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action 62 Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates 64 Valeant Pharmaceuticals International, Inc. - Dormant Projects 73 Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products 75 Discontinued Pipeline Product Profiles 75 ATON-004 75 (bupropion hydrochloride + selective serotonin reuptake inhibitor) 75 brodalumab 75 CVTE-002 76 ezogabine 76 IDP-107 76 IDP-109 76 IDP-115 76 MC-5 76 methylnaltrexone bromide 76 pegaptanib sodium 76 rifaximin 76 RUS-350 77 taribavirin hydrochloride 77 tiazofurin 77 UK-279276 77 Valeant Pharmaceuticals International, Inc. - Company Statement 78 Valeant Pharmaceuticals International, Inc. - Locations And Subsidiaries 81 Head Office 81 Other Locations & Subsidiaries 81 Appendix 89 Methodology 89 Coverage 89 Secondary Research 89 Primary Research 89 Expert Panel Validation 89 Contact Us 89 Disclaimer 90
List of Tables
Valeant Pharmaceuticals International, Inc., Key Information 7 Valeant Pharmaceuticals International, Inc., Key Facts 7 Valeant Pharmaceuticals International, Inc. - Pipeline by Indication, 2016 9 Valeant Pharmaceuticals International, Inc. - Pipeline by Stage of Development, 2016 11 Valeant Pharmaceuticals International, Inc. - Monotherapy Products in Pipeline, 2016 12 Valeant Pharmaceuticals International, Inc. - Combination Treatment Modalities in Pipeline, 2016 13 Valeant Pharmaceuticals International, Inc. - Partnered Products in Pipeline, 2016 14 Valeant Pharmaceuticals International, Inc. - Partnered Products/ Combination Treatment Modalities, 2016 15 Valeant Pharmaceuticals International, Inc. - Out-Licensed Products in Pipeline, 2016 16 Valeant Pharmaceuticals International, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 17 Valeant Pharmaceuticals International, Inc. - Pre-Registration, 2016 18 Valeant Pharmaceuticals International, Inc. - Phase III, 2016 19 Valeant Pharmaceuticals International, Inc. - Phase II, 2016 20 Valeant Pharmaceuticals International, Inc. - Phase I, 2016 21 Valeant Pharmaceuticals International, Inc. - Preclinical, 2016 22 Valeant Pharmaceuticals International, Inc. - Unknown, 2016 23 Valeant Pharmaceuticals International, Inc. - Pipeline by Target, 2016 59 Valeant Pharmaceuticals International, Inc. - Pipeline by Route of Administration, 2016 60 Valeant Pharmaceuticals International, Inc. - Pipeline by Molecule Type, 2016 61 Valeant Pharmaceuticals International, Inc. - Pipeline Products by Mechanism of Action, 2016 63 Valeant Pharmaceuticals International, Inc. - Recent Pipeline Updates, 2016 64 Valeant Pharmaceuticals International, Inc. - Dormant Developmental Projects,2016 73 Valeant Pharmaceuticals International, Inc. - Discontinued Pipeline Products, 2016 75 Valeant Pharmaceuticals International, Inc., Other Locations 81 Valeant Pharmaceuticals International, Inc., Subsidiaries 81
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.